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A Science-Based Sector in the Making: the formation of biotechnology sector in two 
regions  
ABSTRACT This paper analyses two case studies, Skåne-Blekinge in Sweden 
and the Southern-Eastern region in Ireland, to examine different current 
development paths for the biotechnology sector. The aim is to codify the process, 
identifying actions and priorities towards these paths. The national innovation 
systems theory provides the theoretical framework that guided a series of 
interviews in the two regions. The findings demonstrate that the sustainable 
development of a science-based sector does not depend on the original priorities 
or directions, but rather on the level of consistency of those policies and their 
continuous evolution towards a complete systemic value generation system. 
 
KEY WORDS: Value generation systems; Innovation Policy; Biotechnology; 
Regional innovation systems; Case study 
 
1. Introduction 
 
The global biotechnology industry has exhibited high growth rates in terms of research 
achievements, sales and employment (GÖRANSSON and PÅLSSON, 2011), although its 
effect on regional economic growth has been questioned (PISANO, 2006). As a sector, 
biotechnology has been dependent on, and had a major impact on, a range of other sectors 
such as the pharmaceutical sector and the agro-food sector (HOPKINS et al., 2007). The 
biotechnology sector is distinguished from other technology-intensive sectors due to the 
complexity of its activities, the scale of required investments, the barriers to entry and the 
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high thresholds on learning capabilities (PISANO, 2006). To deal with these characteristics, 
focused policies have been implemented with an emphasis on the development of knowledge 
infrastructures and the formulation of institutions to foster technology transfer and innovation 
financing (SENKER et al., 2000). Moreover, several policy measures have included the 
enhancement of collaboration between academia and industry and the formulation of 
production agglomerations through the attraction of foreign investment in large plants by 
multinational companies. However, these characteristics of the sector demand further 
institutional conditions which can address uncertainty, constant knowledge advancement and 
high-risk-financing (BANERJEE and COLE, 2012). 
Innovation systems theory provides an analytical framework to formulate innovation, science 
and technology policies. This theory is based on the idea that innovation is produced through 
an interactive process which includes several different actors and processes (GALANAKIS, 
2006). The theory relates the policy of innovation players to the ability of firms to innovate, 
which in turn affects the wealth of a nation (EDQUIST, 1997). As this is related to national 
competitiveness and performance, studies have been initiated within different disciplines, 
ranging from urban economics to economic geography, institutional and evolutionary 
economics and policy analysis (CARLSSON et al., 2002). The theory furthermore attempts to 
identify the social and economic impact of the process that creates innovation and the impact 
on the actors, the interrelation between the actors across a nation and the mechanisms 
affecting and enhancing knowledge generation and knowledge exploitation (ASHEIM et al., 
2011). Furthermore, several studies highlight the need for innovation policies to deploy 
mechanisms for tailoring a system’s functions to: national characteristics (LUNDVALL, 1992; 
NELSON, 1993); regional innovation system characteristics (TÖDTLING and TRIPPL, 
2005); and, sectoral or technological innovation characteristics, focusing on the development 
of a specific technology or sector.  
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The objective of this paper is to examine different current development paths for the 
biotechnology sector in two distinctive European regions, under the systems of innovation 
theory. The aim is to codify the development process, comparing actions and priorities. This 
codification may support policy-makers in the design of specific measures and programmes in 
the sector, according to the special conditions and priorities in their region.  
The analysis is applied in two European regions with comparable size and level of economic 
development1 – Skåne-Blekinge in Sweden and the Southern-Eastern region of Ireland. The 
two regions have been selected as they represent two distinctive schools of thought for 
development. Skåne-Blekinge, is considered a highly developed area in terms of its research 
capability, constituting part of the broader area of Medicon Valley (with Copenhagen, 
Denmark), and is one of the top-five biotechnology research hot-spots in Europe  
(www.fiercebiotech.com). In Skåne-Blekinge, the life sciences sector involves around 7,000 
individuals and comprises 15% of the total Swedish production volume (value added) with 
the major fields being pharmaceuticals, biotechnology and medical technology (HENNING et 
al., 2010). On the other hand, in the Southern-Eastern region most of the multinational 
companies in the sector had already invested in the region by the 1980s, as they were attracted 
by the incentives provided by the Central Government through the Industrial Development 
Agency (IDA). These incentives included grants, tax incentives, co-funding facilities and 
R&D incentives.  As a result, pharmaceutical and bio-pharmaceutical industry exports 
reached €50 billion in 2010, while pharmaceutical and chemical products accounted for over 
50% of Irish exports. It is estimated that these sectors employ over 24,300 people nationally 
(PHARMACHEMICAL IRELAND, 2011). Already by the middle of 2000s, the 
biotechnology sector employs more than 4,000 people in Ireland, with most of them based in 
the Southern-Eastern region (INTERTRADEIRELAND, 2003). 
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The paper is structured as follows: Section 2 reviews the theory connected to innovation 
systems and knowledge flow partners at national, regional or sectoral level to demonstrate the 
factors that are often used to support policy formation. Section 3 describes the methodology 
used in the analysis of the two case studies. Section 4 provides an analysis of the two 
distinctive regional innovation systems, from the perspective of the policy, the institutional 
formation and the business exploitation environment. Section 5 provides a comparative 
discussion of the two cases with respect to lessons related to the structure, functions and 
performance of the systems, which are codified under a conceptual framework. Finally, the 
concluding section addresses the objective and provides an overall view highlighting the 
complete picture of the development of a science based sector such as biotechnology. 
 
2. Systemic components and knowledge patterns for developing a science-based sector 
 
In principle, innovation systems strategies involve a set of initiatives aiming to enhance the 
capacity of companies to introduce knowledge assets and produce new products or services, 
usually by encouraging collaboration between knowledge users and producers 
(NAUWELAERS et al., 2008). These policy initiatives may be codified to five important 
subsystems (LUNDVALL and BORRAS, 2005), affecting the performance of innovation 
activity: the public sector as policy designer and regulator; the knowledge generation sub-
system; the knowledge exploitation sub-system; the physical set-up of supporting mechanisms 
and institutions, and the institutional set-up of the financial sector. A systems-oriented 
innovation policy, however, attempts to support and often to control both the components and 
the links, which are crucial for the functioning of a system (EDQUIST, 2011). Such policies 
aim to tackle embedded institutional and functional barriers and to accelerate knowledge 
exploration, diffusion and exploitation (TER WAL and BOSCHMA, 2011). 
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2.1. Systemic Components 
The knowledge generation sub-system includes universities; public and private research 
organisations; and knowledge transfer and research funding institutions (ASHEIM and 
COENEN, 2005). The knowledge generation process is enhanced by: intra-national (e.g. the 
European Union Framework Programmes), national and regional science and innovation 
policies; general knowledge infrastructures (soft infrastructure); the funding of basic and 
applied research activities; and innovation-supporting institutions, such as science and 
technology parks and technology and knowledge networks.  
The impact of the knowledge generation sub-system, depends on the ability of the system to 
apply and exploit these results. Therefore, novel results are introduced, producing innovative 
products and services or business models; i.e. firms that generate appropriate value chains and 
trading relations. This part of the system is affected by the way in which firms are organized, 
cooperate and interact. Biotechnology companies have used several business models2 to 
develop their activities and to deliver value, based on differentiated capabilities, value chain 
position and specialisation. However, the density of research, the scale of investment that is 
required and the complexity of manufacturing activities have encouraged the emergence of 
alternative business models, such as the “technology platforms” and cluster generation 
(CASPER, 2007), differentiating the processes of value creation and sustainability paths. 
In cases where knowledge, complexity and uncertainty are intrinsic features creating high 
capital costs, the role of innovation-supporting institutions and innovation systems’ activity 
seems to be particularly significant. Unsurprisingly, due to the high technological uncertainty 
and organisational complexity that characterise the biotechnology sector, its growth 
increasingly requires system-oriented innovation supporting mechanisms, oriented to 
knowledge diffusion and alternative funding. Therefore, innovation-supporting institutions, 
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providing common infrastructure (e.g. research, testing and prototyping labs), novel 
knowledge transfer, and networking mechanisms, which specialise in and prioritise 
biotechnology, are prerequisites for the sector’s growth (PISANO, 2006).  
Finally, the institutional set-up of the financial sector plays a crucial role in the sustainability 
of the system even though R&D active firms finance this activity primarily out of cash flow 
(HALL, 2002) with external finance as a secondary source. External R&D investment has a 
higher level of impact when it is bank-based (e.g. venture capitalists or investment banks) 
rather than market-based - i.e. stock market capitalisation. This relates to the information 
asymmetry between the firm and the potential investors. The banking system, which shows 
maturity and understanding of the sectoral conditions, has the capacity to investigate the 
potential of such long term investments in greater depth. Furthermore, in many cases national 
systems have provisions for tax relief on R&D investment, matching funds or public 
guarantees for private R&D activities or internal investment for firms to gain operational 
efficiencies. These interventions may be summarised in three categories: grants, loans or 
government contracts; incentives and tax law provisions; and national or international 
research collaborations (RAHM et al., 2000). 
The nature of the formation of the components of a science-based sector, such as 
biotechnology, gives rise to the first research question: 
RQ1: What are the distinctive characteristics of a science-based regional innovation system 
that derive from the different formation path of its components? 
 
2.2. Knowledge flow patterns 
The growth of biotechnology, is affected by knowledge creation and diffusion patterns. 
Knowledge has been seen as an object and as an action (knowing), in which progress is made 
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through active engagement with the world. This view broadens the distinction of knowledge 
between tacit and explicit to the importance of social capital, or network ties (ADLER and 
KWON, 2002) that provide access to resources. Knowledge generation and diffusion, yet, 
tends to be highly localised (MIGUÉLEZ AND MORENO, 2015) especially for sectors such 
as biotechnology, pharmaceuticals and chemicals, in contrast to electronics and information 
and communication technologies (ADAMS, 2002). BOTTAZZI and PERI (2003) for example 
demonstrate the locality of knowledge generation measuring the effect of doubling R&D 
investment in a region compared to a neighbouring one. Their results – 80-90% increase of 
new ideas generation on the region where the investment took place in comparison to 2-3% in 
the neighbouring one – demonstrates the spatial effect, although others have found an existing 
but much lower importance (e.g. AUTANT-BERNARD and LESAGE, 2011).  
 
The institutional factor and relevant incentives have been found to be determining factors for 
both generating and diffusing knowledge (AUTANT-BERNARD et al., 2013), thus 
highlighting the important role of innovation policies and priorities. Furthermore, diffusion is 
highly related to mobility of skilled employees (SINGH and AGRAWAL, 2011), the ability 
of a region (or a firm) to “anchor” the mobile skilled staff (LOWE and GERTLER, 2009) and 
to facilitate productive between knowledge creators and the industry. 
 
Universities with their specificities and distinctive characteristics, occupy a central position in 
the generation of knowledge. Nevertheless, they are not naturally connected with industry and 
its priorities (AUTANT-BERNARD et al., 2013). This connection though – keeping the 
identity of each side – is considered as very important for knowledge-based economies 
(FORAY and MAIRESSE, 2002), as interactions benefiting researchers, institutions and the 
private sector. The inter-industry contacts and networks further stimulate the exchange of 
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knowledge since knowledge generation is a collective activity among a variety of agents. 
BURT (1992) suggests that social relations and channels provide benefits in the forms of 
access, timing and referrals. Network ties provide the channels – or their absence creates a 
barrier – for information transmission, compensating for the absence of geographical 
proximity (GUAN, et al., 2015). The configuration of these ties – density, connectivity, 
stability over time, openness and hierarchy – affect the development of intellectual capital 
(ADLER and KWON, 2002).  
 
Thus, the challenge is to initiate and sustain the collaboration between all the different agents 
and to implement a variety of mechanisms capturing and absorbing local and external 
knowledge (AUTANT-BERNARD, et al., 2013; MUKHERJI and SILBERMAN, 2013). In 
the case of biotechnology, GERTLER and LEVITTE (2005) suggested that highly planned 
knowledge networks that spread across nations play a significant role in innovation, breaking 
the trend of localised knowledge flows. However, they observed that this may take place 
during the later stages of the innovation process and not equally in the early developing stages. 
For regions in which biotechnology activity is still in an emerging stage activities are 
concentrated around regional public or private champions. However, even then, they search 
for knowledge and complementary skills from the international terrain on the basis of former 
international social and professional networks (VALE and CARVALHO, 2013). 
 
Finally, the intensity of knowledge flows and commitment to innovation enhancing 
interactions between MNEs and domestic firms depends on the perceived advantage from 
both sides. Furthermore, the absorptive capacity of the domestic firms and the 
technology/productivity gap may be the drivers of knowledge adoption and flow as a result of 
foreign direct investments  (CRESCENZIA, et al., 2015). Internationalised domestic firms 
10 
 
have a lower potential to learn from MNEs or to perceive collaborations as beneficial as they 
usually tend to have higher productivity rates already and are more likely to be direct 
competitors in international markets (CRESCENZIA, et al., 2015). 
 
These distinctive patterns of knowledge flow give rise to the second research question: 
RQ2: How does the formation path of a science-based regional innovation system 
differentiate its ability to generate, diffuse and exploit knowledge and skills? 
 
3. Methodology 
This paper follows an abductive methodology (REICHERTZ, 2007). The study analyses two 
empirical case-studies (YIN, 1994) and codifies the distinctive processes of the formation of 
the two systems. Two NUTS II regions have been used to collect data: the Skåne-Blekinge 
region of southern Sweden and the Southern-Eastern region of Ireland. Over the last decade 
the case study approach has been used extensively in a wide range of academic disciplines 
(COLLIS and HUSSEY, 2003) such as, economics, business and innovation studies, and 
public policy.  
The data collection based on the analysis of a variety of documents, including academic 
journal articles, policy reports (for example from FORFAS, the European Commission, 
OECD and VINNOVA), company reports and relevant websites (for example, those of the 
Industrial Development Agency or Invest in Skåne). As a second step, twenty in-depth 
interviews, based on semi-structured questionnaires, were conducted during two research 
visits to the two regions (Appendix A, Table A.1). The interview questions investigated 
perceptions related to the impact of innovation policies; the evolution of regional innovation 
systems; and, the activity of biotechnology companies. The interviews were conducted with 
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staff at policy-making institutions, regional actors and mechanisms, business associations, 
technology transfer offices in the largest universities, business development organisations, 
science parks and incubators. The interviews were conducted anonymously and the results 
summarised in a codification for each case (Complete transcript of the interviews are 
available at ANGELAKIS, 2011). Finally, the knowledge application and exploitation sub-
systems have been explored through research on the company websites. The validity of the 
information has been cross-checked with relevant official databases (e.g. Medicon Valley, 
IDA company database). 
 
4. The policy and institutional formation in the two regions 
In the Swedish case innovation policy was a central policy issue as early as the 1940’s (the 
Swedish Technical Research Council - TFR was launched in 1942 and replaced in 1968 by 
the Swedish National Board for Technical Development – STU). Industrial policy, during the 
1980s, focused mainly on restructuring key industrial sectors and included in the policy mix a 
first wave of funding aiming at the establishment of research infrastructure. During the 1990s, 
activities and funding gradually shifted toward the promotion of applied research, the 
enhancement of partnerships and collaborative programmes between industry and public 
research institutions and universities. This aimed to encourage the exploitation of knowledge 
and networking between academics and the private sector. These directions became central to 
the national agenda in the early 1990s’ with the establishment of Swedish National Board for 
Technical and Industrial development (NUTEK) - merging the STU, the Agency for 
Industrial Development (Industriverket) and the Energy Agency – and its successor, the 
Swedish Governmental Agency for Innovation Systems (VINNOVA), in 2001.  
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Innovation policy in Ireland highlights the gradual shift from the initial paradigm of economic 
protectionism (e.g. the Control of Manufacturers Act) to the introduction of measures to 
attract significant foreign direct investments (FDI) as early as the 1960s. Innovation policy 
became a crucial part of growth strategies during the following decades. The Science and 
Technology Act in 1987 constituted a major step in building Irish technology policy, by 
creating a framework for an enhanced research infrastructure and the need for a prosperous 
indigenous industry (HILLIARD and GREEN, 2005). The first policy in relation to 
biotechnology derived from that (the National Biotechnology Programme in 1987), promoting 
collaboration between industry and academia (SPRU, 2007). As a result BioResearch Ireland 
was formulated (later the Biotechnology Directorate of Enterprise Ireland). Nonetheless, by 
the middle of the 1990s, the performance of medium/large Irish-owned industry proved 
disappointing (see for example the Culiton Report, 1992). Although Ireland had received the 
highest level of FDI in Europe by almost every major MNE in the sector, the collaboration 
and exploitation of the rich knowledge-base of its universities3 was poor (HEWITT-
DUNDAS and ROPER, 2008). Therefore, the policy progressed, aiming at a more balanced 
strategy than the FDI-based growth path and an innovation agenda designed with the support 
of the EU structural funds and objectives that stated in the regionalisation agenda (IDA, 2011). 
The institutional and systemic characteristics of the two regions are summarised in Appendix 
B, Table B.1. 
4.1. The supportive components in the two regions 
The Swedish innovation policy paradigm is based on the application of “systemic 
instruments” on fostering forward-looking aspects of policies, especially though innovation 
policy planning coordinated by organizations such as VINNOVA. This direction derived 
directly from the “triple helix” concept, which was promoted by the European Union’s policy 
framework and realised largely through VINNOVA’s public-private collaborative schemes. 
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These partnerships were driven by the knowledge capacity of Lund University4 (Appendix A, 
Table A.3) and the intermediate structures that developed around the University, for example 
IDEON (Appendix A, Table A.4).  
These trends have been further intertwined with European public research, technology and 
innovation policies which no longer remain exclusively in the hands of national authorities 
but are supplemented by regional innovation policies or transnational programmes 
(KUHLMANN, 2001). Following these, Sweden attempted to distinguish innovation policy at 
regional level, by the creation of a 10-year initiative to form an elected regional government 
(COENEN, 2007). This reform included a shifting of responsibility for economic 
development at regional level, through the regional growth agreements (Regionala 
TillväxtAvtalen). The regional agreements and programmes were following national policies 
(e.g. the Regional Development Programme for Skåne 2009–2016), which were designed 
using “functional regions” instead of “territorial regions” (OECD, 2006). Functional regions 
used by VINNOVA in order to promote internationally competitive regional innovation 
systems (VINNOVA, 2007). The major benefit from the regional agreements was the increase 
of understanding across the national innovation actors5 of the role of science in economic 
growth and the identification of the so-called “third role” of universities. The policies 
followed eventually led to structural changes in the Swedish industry, improving 
manufacturing employment, productivity and intensified the activities in high-technology 
sectors (BITARD et al., 2008).  
In the Southern-Eastern , the investment in knowledge infrastructure or in supporting 
mechanisms came later (initiated in the late 1990s) and were much more fragmented and 
limited in scale in comparison to Skåne-Blekinge. This fragmentation occurred as these 
facilities spread across the academic and research structures (Appendix A, Table A.5), 
limiting their ability to generate synergies and efficient networking. The emergence of Forfás 
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(established in 1996) led to the formulation of an industrial plan, which reconfirmed 
biotechnology as a priority sector (FORFAS, 2011). 
The same recognition stated by the Technology Foresight and put forward in 1997 by the Irish 
Council for Science, Technology and Innovation. In the same period, Enterprise Ireland (EI) 
launched the “Building Biotech Businesses” programme to support indigenous start-ups, 
encouraging the establishment of at least 40 biotechnology companies (SENKER et al., 2000). 
An important advantage for Ireland, in parallel to other incentives for established firms and 
institutions, was the nation’s connection to the Anglophone world which attracts highly 
skilled personnel and researchers (HEWITT-DUNDAS and ROPER, 2008).  
Research related investment was accelerated during the period 2000-2010. In 1998, HEA 
launched the Programme for Research in Third-Level Institutions (PRTLI), one of the largest 
funding programmes in the country, which was co-funded by the European Union Structural 
Funds and the European Regional Development Funds. PRTLI supported an extensive 
biotechnology research infrastructure. During the period 2000-2007 this investment averaged 
to €22.4 million annually (SPRU, 2007), specifically targeting the development of 
infrastructure and research activities for universities and technology institutes. In 2011, HEA 
provided €131million for the development of the Trinity Biomedical Science Institute, 
indicating a concentration of funds on a select few national champions. Around the same 
period, the Technology Transfer Strengthening Initiative was created by EI in 2006 with a 
budget of €30 million, which still remains a major funding source for such mechanisms. 
4.2. The exploitation dimension in the two regions 
A significant difference between the two regions is the absence of MNEs in Skåne-Blekinge 
while in Southern-Eastern more than 20 MNEs are present and remain the major employer. In 
Skåne-Blekinge, the rise of new ventures benefited from the long-term research focus on the 
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biotechnology sector, the collaboration initiatives and the funding mechanisms. It is estimated 
that in the broader Medicon Valley, the number of biotechnology firms exceeds 140. About 
half of these (68 firms) are start-up firms in Skåne-Blekinge. The trend accelerated after 2006 
(Appendix B, Table B2), since when the total number of firms has doubled and university 
spin-offs tripled. From the 37 spin-offs in the region, operating after 2006, 35 originated from 
Lund University (LU), demonstrating the impact that it has had in the sector, while only a few 
emerged as spin-outs or subsidiaries of pharmaceutical companies (3 and 2 respectively). 
The Southern-Eastern region in Ireland has seen a similar number of start-ups recently, with 
67 biotechnology companies operating in the region since 2006. However, only 40% of them 
are university spin-offs (Appendix B, Table B2). One in ten of the start-ups is a result of the 
Elan spin-out phenomenon6, which caused a significant exodus of professionals toward 
private spin-outs (CURRAN et al, 2011). A further 25% are direct subsidiaries of MNEs.  
In both cases, the majority of the start-ups remain micro (with less than 10 employees) or 
small (between 10 and 50 employees) (Appendix B, Table B2). This is especially true in 
Skåne, where 7 out of 10 remain micro firms. University spin-offs in the Southern-Eastern 
have had a significantly larger impact on employment and together with the MNEs of the 
sector account for approximately 10% of total employment.  
Regarding the sources of finance of the various start-ups, our research shows that 82% of the 
companies in Skåne-Blekinge secured investments by national or international private and 
public venture capital funds, or regional and sectoral ones (e.g. LU Bio) that are co-funded by 
European Union Programmes (Appendix B, Table B3). Their funding strategies follow a risk-
spread multi-partite approach, including founders, holding companies and venture capital 
participation. In Southern-Eastern, venture capital funds were initiated by the backing of 
Enterprise Ireland, which directly provided funding or guarantees for investment from 
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international investment funds. Two thirds of their funding is directed toward spin-out 
activities which are considered more mature with a lower risk level, although their number is 
about half that of the spin-offs. MNE’s subsidiaries in Southern-Eastern follow an investment 
pattern based on public offerings and partnerships, supported by IDA grants or facilities. This 
orientation, chosen by around 40% of the firms in Southern-Eastern, may lead these firms to 
under-invest in long-term R&D projects as shareholders in general tend to invest in more 
mature, lower risk projects that present a fast, profitable outcome. However, this type of 
investment in Skåne-Blekinge is much less frequent, with only 18% of firms taking this 
finance route. Appendix B, Table B.4 summarises the business environment in the two 
regions. 
4.3. Perceptions of innovation policy and structures in the two regions 
A major difference between Skåne-Blekinge and Southern-Eastern is the importance of local 
actors. In Skåne-Blekinge, many local actors took centre stage after the 1990s as the result of 
regional agreements. The distinction between functional and territorial regions partly limited  
the ability of the regional stakeholders to be the drivers of regional level policy. In Southern-
Eastern, in contrast, the national policy actors directed the activities throughout the whole 
period, spreading activity and funding across the several actors. Interviewees wondered 
however, whether these activities would be viable if support is withdrawn (Appendix B, Table 
B.5).  Furthermore, they noted that innovation policy is often affected by the competing 
interests of several national actors7 with no actual consultation from the two newly formed 
regions - the Border Midland & Western Region (B.M.W.) and the Southern and Eastern 
Region (S&E). Furthermore, in the Southern-Eastern the interviewees questioned the 
consequences of the policy to attract MNEs. The Southern-Eastern, indeed, has attracted 
major MNEs through direct support in the sector (e.g. IDA business park support). The policy 
assumed, nevertheless, that R&D and the collaborations with the regional research institutions 
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would have been led by the major MNEs that had invested productively in the region. This 
however, did not materialise and led to low R&D activity of the industries or to only sporadic 
collaborations with universities and research institutions which proved unsustainable after the 
relevant programmes were completed. The interviewees pointed out that both indigenous and 
multinational biotechnology companies had received significant support by the IDA, in 
developing productive activities, requiring skilled employment that attracted international 
attention. Now, though, it is necessary to support organic growth in order to sustain their 
development. They raised the importance of increasing R&D as part of total investments in 
Southern-Eastern and stressed the evident need for still greater effort in the development of 
more local strategic collaborations. The interviewees, moreover, felt that despite occasional 
public-private R&D collaborations with major firms (e.g. Pfizer, GSK, Eli Lilly) and the 
support of spin-offs from EI, the sponsored programmes had had limited impact. This was due 
to the low level of initial interest in knowledge exploitation by the academic community, the 
limited scale of R&D capacity in the MNEs and the general underdeveloped area of seed 
capital support.  
The limited seed capital support and reluctance from academics to engage in entrepreneurial 
activities was noted by the interviews in Skåne-Blekinge, too. In this case, though, they 
praised the importance of actors such as University holding companies to increase such 
awareness and the support mechanisms to start-ups providing them access to world class 
R&D infrastructure8, allowing them to develop specialised intermediate products, treatments 
and therapies. Furthermore, they are able to provide specialised services to other firms 
through service contracts.  
 
The size of the firms in the sector remains an impediment in both cases, raising issues related 
to the integration of productive activities, the scale of production and the ability to generate 
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multiple product and service pipelines as a spread-risk strategy (FISKEN and 
RUTHERFORD, 2002). The interviewees, in both cases, stressed their perception of the 
dependency of spin-offs on national policy tools and universities’ research activities because 
of their micro/small size. As ASHEIM and COENEN (2005) showed the size of a company is 
strongly associated with its origin. University spin-offs are usually small and frequently 
single-employee firms. This dependency however, was seen as a significant limitation in 
terms of the internationalisation of their activities and their potential to grow. Furthermore, 
the high degree of specialisation imposes three major challenges in both cases: a) sustainable 
value generation, b) the proximate market demand fluctuations and margins and c) the 
technological downgrading. These features create a business environment requiring a further 
evolving portfolio of localised priorities, policies and business models related to knowledge 
accumulation, technology improvement, networking and open innovation (CHESBROUGH, 
2003). Our research in Skåne-Blekinge noted that despite the proximity of the region to the 
Copenhagen region, which creates a pulling agglomeration for large pharmaceutical and 
biotechnology companies, only about a third of the firms have an international presence, 
usually through the provision of specialised services to larger users. However, in Southern-
Eastern the interviewees underlined as beneficial the dependence of the start-ups on the 
MNEs that are based in the region, since they provide them with specialised services or 
licensed products, while one fifth specialise in diagnostics and bio-analytic services.  
 
5. Discussion 
The different policies and prioritisation in the two regions has created two distinctive systems. 
This distinction is due not to the nature of actors active nationally or regionally, but rather to 
the policy and knowledge flow patterns that have been created and sustained. Policy patterns 
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determined that the initiation of regional innovation and knowledge stakeholders was 
prioritised, as was their interactions and their sustainability over time (RQ1). 
In parallel, this distinctive path formation differentiated the ability of the two systems to 
generate, diffuse and exploit knowledge and skills (RQ2). In Sweden, as early as the 1980s, 
the development of the biotechnology sector was pro-actively supported through massive 
investments in knowledge infrastructures (supply-side orientation) (VINNOVA, 2007; 
VINNOVA, 2010). This investment, which was accompanied by the regionalisation of 
policies and the recognition of the third role of universities by the stakeholders, was 
concentrated in and around Lund University. LU’s activities and incentives reinforced the 
original strengths of its research, following a largely “inside-out” direction (from endogenous 
knowledge generation to spin-off activities). As a result, LU became the engine of growth for 
biotechnology in the region. This long-term focus created a critical mass of knowledge 
generation and attracted international attention and recognition. The sustainability of the 
system in Skåne depends on the ability to foster, or indeed initiate, appropriate value chain 
networks, through its international knowledge networks. Such networks only partly explore 
the knowledge generation sphere, as they depend on the entrepreneurial nature of the 
participants. Therefore, in a second wave of investment a set of measures has been put in 
place oriented to triple-helix collaborations, financed mainly from VINNOVA, SSF and 
knowledge transfer institutions. These measures reinforced commercialisation processes and 
collaborations (e.g. IDEON science park, LU Innovation Systems), encouraging further start-
up creation. Furthermore, there was a strong economic agglomeration between universities 
and their spin- offs where local institutions mediate on connecting with financial institutions 
complementary to scientific networks. As a result, it is possible to identify an intense 
knowledge flow amongst universities and spin-offs, formulating a local “open self-sustained 
innovation paradigm”, building networks that are characterised by a primarily socially 
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embedded cohesion (HITE and HESTERLY, 2001). Despite this, the participation of start-ups 
of the region into international value chains remains a challenge. 
The policy tools and programmes in Ireland have focused mainly on encouraging the 
establishment of productive operations either by foreign-owned firms across the country 
through FDI (“outside-in” orientation), or indigenous start-ups (FORFAS, 2000). These 
policies and programmes directed a first wave of foreign investments and spin-offs within the 
period from 1995 to 2000 and a second wave of MNEs interaction in the post-2000 period 
defining diverse needs, attractive to international value chains, forming local business and 
productive hubs. The Southern-Eastern biotechnology financial and investment initiatives are 
characterised by a risk-averse approach regarding value creation. Its sustainability depends on 
the ability of the dedicated-biotechnology firms (DBFs) to provide these specialised services 
and products, remain innovative, absorb knowledge and sustain productivity levels. The latter 
is connected with their knowledge absorption level and that of the region, which still depends 
on the role of national policies and supportive actions. In the past, these actions were 
fragmented and sporadic. These type of relations followed a path-dependent model, often 
within embedded and “arm’s-length” relations.  
6. Conclusions 
The distinct characteristics of the two regions, codified in Appendix C, Figure C.1 and Figure 
C.2, give rise to a regional value generation concept for the two cases that demonstrates the 
level of achievement in the two regions under the theoretical lenses of the innovation systems 
theory. These illustrations follow the five subsystems of innovation systems theory, 
highlighting the regional characteristics that have been derived by the different formation 
paths. 
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Innovation systems theory offers the generic intellectual framework to study innovation 
systems although it lacks sound suggestions regarding the process of formulating an overall 
system. The analysis of the two case studies presents an overall path of the flow of a value 
generation system’s development, towards a complete and robust innovation system. These 
flows illustrate the importance of a coherent policy and investment approach incorporating the 
next generation of development. Synthesising the two distinctive frameworks (Figure 1) 
demonstrates two possible paths of projected development – the holistic “Regional Value-
Generation System”. Such projection may take into consideration the limitations of resources 
(capital, infrastructure, knowledge and human), the level of development or sophistication of 
its social capital and the evolutionary nature of regional and sectoral development. 
In the case of Skåne-Blekinge, therefore, the next steps may include the enhancement of 
international networking activities in order to foster value-chain networks. Moreover, further 
initiatives are needed to enhance the internationalisation of start-ups, incorporating, for 
instance, open innovation business models and novel technology opportunities (e.g. 
technology platforms). In the case of Southern-Eastern, on the other hand, the next steps in its 
development could include further investment in basic and applied research oriented activities, 
selecting and investing in a few clear regional champions that can actually lead in the 
international research field. Moreover, the institutional and financial support mechanisms 
could be consolidated to support such champions. 
********************** 
Figure 1 - Insert here 
********************** 
 
The proposition for the Southern-Eastern derives from the analysis of the two cases that 
expressed the need of concentrating resources on specific actors so as to avoid fragmentation. 
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This aims to create poles of agglomeration or “champions”. In both cases, when the resources 
(financial, infrastructure and human) were targeted, it created or attracted international 
champions. Those actors managed to evolve and develop adequate sophistication to reinforce 
their growth. This concentration is demonstrated especially by the relative success of LU 
compared to the Irish case where the knowledge generation and transfer system is fragmented. 
Politically, this is often hard to defend, as there are always local pressures. In one sense, this 
type of concentration is the reason for the successful formation of MNEs in comparison to the 
small spin-offs that often fail to grow sustainably. On the other hand, the actors that manage 
to grow in importance reinforce the original policies, influencing them only indirectly. The 
issue of the direction of the policies was raised in both regions, although it is questionable 
whether in the early stages these actors had the maturity to provide viable policies. As they 
progress in maturity, they are able to reinforce policies, which support their priorities. Thus, 
the presence of a knowledge champion, such as LU,  has an influence on the regional 
priorities for Skåne-Blekinge and the dominant presence of MNEs dictates the industrial and 
economic policies of Ireland. 
An investigation into the different patterns of development that emerge across the world could 
expand this work further. For example, based on the extended use of information technologies, 
which claim to break borders, it would be possible to observe the creation of “virtual (or 
“open”) innovation systems”. These could be defined as interconnected stakeholders across 
different sectors, knowledge subjects, regions and nations where knowledge flows could be 
generated and transferred independent of the physical location. Furthermore, thematic clusters 
that engage academic, research and industry stakeholders from different fields (e.g. 
information technologies, physics, maths, engineering, hospitals and firms) and multi-level 
policy actors have been developed over the last decade across the world. The Catapults in the 
UK, Toronto’s life sciences complex, the Pôles de Compétitivité in France, or the BioRegio 
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programme in Germany (e.g. Heidelberg BioRegio cluster in Baden-Wurttemberg) represent 
such approaches at national level (FISKEN and RUTHERFORD, 2002; LOWE and 
GERTLER, 2009). 
The further evolution of the Regional Value-Generation System may link directly with the 
governance structures of such mechanisms (bringing together research institutions, academia, 
private firms and even patients) and the contractual arrangements regarding the exploitation 
of their results. Open innovation arrangements in the biotechnology sector are here to stay and 
benefit from the specialisation of DBFs. Thus, innovative ways of organizing their 
development, financing their risky propositions, for example through crowdsourcing 
techniques, and commercializing biotechnologies will be crucial to growth in the business and 
the sector (ASHEIM, et al., 2011; PISANO, 2015).  
In conclusion, this research reveals that for an innovation system to become self-sustaining 
requires consistency in path choice and a long-term coherent development. The original 
priorities or directions that are chosen define which relevant sub-systems should be prioritised 
for development by means of continuously evolving public policies and supportive actions. 
The realisation of this evolutionary strategy may lead even a small nation to succeed in a 
science-based sector, such as the biotechnology. 
 
NOTES 
                                                          
1 GDP per capita, 2010: €37,300 for Sweden; €35,000 for Ireland. GDP per capita, 2010, PPS: 
€30,200 for Sweden; €31,600 for Ireland (Eurostat). 
2 The dominant business models in biotechnology can be identified as: a) small or medium 
R&D oriented firms (Dedicated Biotechnology Firms or DBFs), which originate as university 
24 
 
                                                                                                                                                                                     
spin-offs or spin-outs from major firms and develop specialised research, license intellectual 
property or provide R&D services; b) large multinational companies, conducting world-class 
research and commercialization functions under vertical or ‘virtual’ integrations (FISKEN 
and RUTHERFORD, 2002). 
3 Major knowledge actors in the region, Appendix A, Table A.2. 
4 More than 30 companies have received support in the form of facilities through the IDEON 
science park, 14 from other incubators and 25 from other independent business parks around 
the region. In the case of Southern-Eastern, 19 firms are based in incubators, MNEs are 
mostly located in independent sites or IDA business parks. 
5 Main national actors in Ireland and diffusion institutions in Southern-Eastern, Appendix A, 
Table A.2 and Table A.6. 
6 Elan Corporation was launched in 1969 specialising in drug delivery systems. After 2002, a 
divesting strategy caused spin out effects (i.e. such as AGI Therapeutics) (CURRAN et al, 
2011). 
 
REFERENCES 
ADAMS, J.D. (2002) Comparative localization of academic and industrial spillovers, Journal 
of Economic Geography 2, 253–278. 
ADLER, P. S. and KWON, S-W. 2002 ‘Social capital: prospects for a new concept’, Academy 
of Management Review, 27 (1), 17-40. 
ANGELAKIS, A. (2011) Regional Competitiveness and Research, Technology and 
Innovation Policies, PhD Thesis, University of Crete, Greece.  
25 
 
                                                                                                                                                                                     
ASHEIM, B. and COENEN, L. (2005) Knowledge bases and regional innovation systems: 
Comparing Nordic clusters. Research Policy 34, 1173-1190.  
ASHEIM, B., BOSCHMA, R. and COOKE, P. (2011) Constructing Regional Advantage: 
Platform Policies Based on Related Variety and Differentiated Knowledge Bases. Regional 
Studies 45, 893-904.  
AUTANT-BERNARD, C., FADAIRO, M. and MASSARD, N. (2013) Knowledge diffusion 
and innovation policies within the European regions: Challenges based on recent empirical 
evidence. Research Policy, 42, 196-210. 
AUTANT-BERNARD, C. and LESAGE, J. (2011) Quantifying knowledge spillovers using 
spatial econometric tools. Journal of Regional Science 51, 471–496. 
BANERJEE, P.M. and COLE, B.M. (2012) A study of biotechnology start-ups undergoing 
leadership change: Antecedents of change and endogenous performance consequences. 
Technovation 32, 568-578.  
BITARD, P., EDQUIST, C., HOMMEN, L and RICKNE, A. (2008) Reconsidering the 
paradox of high R&D input and low innovation: Sweden. In: EDQUIST, C. and HOMMEN, 
L. (Eds.) Small Country Innovation Systems Globalization, Change and Policy in Asia and 
Europe, Edward Elgar.  
BOTTAZZI, L. and PERI, G. (2003) Innovation and spillovers in regions: evidence from 
European patent data. European Economic Review 47, 687–710. 
BURT, R. (1992) Structural holes versus network closure as social capitl. In: LIN, N., COOK, 
K., and BURT, R. (Ed.) (2001) Social Capital: Theory and Research. NY: Aldine DE Gruyter.  
26 
 
                                                                                                                                                                                     
CARLSSON, B., JACOBSSON, S., HOLMÉN, M. and RICKNE, A. (2002) Innovation 
systems: analytical and methodological issues. Research Policy 31, 233-245.  
CASPER, S. (2007) How do technology clusters emerge and become sustainable?: Social 
network formation and inter-firm mobility within the San Diego biotechnology cluster. 
Research Policy 36, 438-455.  
CHESBROUGH, H. (2003) Open Innovation: The New Imperative for Creating and Profiting 
from Technology. Harvard Business School Press, Boston.  
COENEN, L. (2007) The role of universities in the regional innovation systems of the North 
East of England and Scania, Sweden: providing missing links?. Environment and Planning C: 
Government and Policy 25, 803-821.  
COLLIS, J. and HUSSEY, R. (2003) Business Research: A Practical Guide for 
Undergraduate and Postgraduate Students. Palgrave Macmillan., UK.  
CRESCENZIA, R, GAGLIARDIA, L. and IAMMARINO, S. (2015) Foreign multinationals 
and domestic innovation: Intra-industry effects and firm heterogeneity, Research Policy 44, 
596-609.  
CURRAN, D., VAN EGERAAT, C. and O'GORMAN, C., (2011) New Entrants and Inherited 
Competence: The Evolution of the Irish Biotech Sector. NIRSA Working Paper Series 66. 
EDQUIST, C., (Editor) (1997) Systems of Innovation: Technologies, Institutions and 
Organizations, Pinter. 
EDQUIST, C. (2011) Design of innovation policy through diagnostic analysis: Identification 
of systemic problems (or failures). Industrial and Corporate Change 20, 1-29.  
27 
 
                                                                                                                                                                                     
ENTERPRISE IRELAND (2011) Technology Transfer in Ireland 2007-2010. Enterprise 
Ireland, Dublin.  
FISKEN, J. and RUTHERFORD, J. (2002) Business models and investment trends in the 
biotechnology industry in Europe. Journal of Commercial Biotechnology 8, 191-199.  
FORAY, D. and MAIRESSE, J. (2002) The knowledge dilemma and the geography of 
innovation. In: FELDMAN, M. and MASSARD, N. (Eds.), Institutions and Systems in the 
Geography of Innovation. Kluwer Academic Publishers, Boston/Dordrecht/London, pp. 35–
54. 
FORFAS (2000) Enterprise 2010: A New Strategy for the Promotion of Enterprise in Ireland 
in the 21st Century, Dublin: Forfás. 
FORFAS (2011) Analysis of Ireland’s Innovation Performance, Dublin. 
GALANAKIS, K. (2006) Innovation process. Make sense using systems thinking. 
Technovation 26, 1222-1232.  
GERTLER M. S. and LEVITTE Y. M. (2005) Local nodes in global networks: the geography 
of knowledge flows in biotechnology innovation, Industry and Innovation 12, 487–507. 
GÖRANSSON, B. and PÅLSSON, C.M. (2011) Strategies for appropriation of biotechnology. 
In: GÖRANSSON, B. and PÅLSSON, C.M. (Eds.) Biotechnology and Innovation Systems: 
The Role of Public Policy. Edward Elgar, Cheltenham, UK - Northampton, MA, USA., pp. 1-
10.  
GUAN, J., ZHANG, J. and YAN, Y. (2015) The impact of multilevel network on innovation. 
Research Policy, 44, 545-559. 
28 
 
                                                                                                                                                                                     
HALL, B. (2002) The Financing of Research and Development. Oxford Review of Economic 
Policy 18, 35-51.  
HENNING, M., MOODYSSON, J. and NILSSON, M. (2010) Innovation and Regional 
Transformation: From Clusters to New Combinations. Region Skane, Malmo, Sweden.  
HEWITT-DUNDAS, N. and ROPER, S. (2008) Ireland's Innovation Performance: 1991-2005. 
Quarterly Economic Commentary, Vol. 2008 (2), 06.2008, 46-68. 
HILLIARD, R. and GREEN, R., (2005) Governance and Institutional Change in Ireland. In: 
Organisation for Economic Co-operation and Development, OECD (Ed.), Governance of 
Innovation Systems, Volume 2. Case Studies in Innovation Policy. OECD, Paris, pp. 43-64.  
HITE, J. and HESTERLY, W. (2001) The evolution of firm networks: from emergence to 
early growth of the firm, Strategic Management Journal 22, 275–286. 
HOPKINS, M.M., MARTIN, P.A., NIGHTINGALE, P., KRAFT, A. and MAHDI, S. (2007) 
The myth of the biotech revolution: An assessment of technological, clinical and 
organisational change. Research Policy 36, 566-589.  
IDA (2011) Agenda 2000 Regionalisation Arrangements Industrial Development Agency, 
Ireland, http://www.idaireland.com/, access at: 09/03/2011.  
INTERTRADEIRELAND (2003) Mapping the Bio-Island. A North/South Study of the 
Private Biotechnology Sector. InterTradeIreland, Co. Down, Ireland.  
INVEST IN SKANE, http://www.investinskane.com, access at: 12/05/2010. 
29 
 
                                                                                                                                                                                     
KUHLMANN, S. (2001) Future governance of innovation policy in Europe—three scenarios, 
Research Policy 30, pp. 953–976. 
LOWE N. and GERTLER M. (2009) Building on diversity: institutional foundations of 
hybrid strategies in Toronto’s life sciences complex, Regional Studies 43, 589–603. 
LUNDVALL, B. Å., (Editor) (1992) National Systems of Innovation. Toward a Theory of 
Innovation and Interactive Learning, Pinter, London. 
LUNDVALL, B. Å. and BORRAS, S. (2005) Science, Technology and Innovation Policy. In: 
FAGERBERG, J., MOWERY, D., NELSON, R. (Eds.), The Oxford Handbook of Innovation. 
Oxford University Press, Oxford, pp. 599-631.  
MIGUÉLEZ, E. and MORENO, R. (2015) Knowledge flows and the absorptive capacity of 
regions. Research Policy, 44, 833-848. 
MUKHERJI, N. and SILBERMAN, J. (2013) Absorptive capacity, knowledge flows, and 
innovation in US metropolitan areas. Journal of Regional Science 53, 392–417. 
NAUWELAERS, C. and WINTJES, R., (Ed.) (2008) Innovation Policy in Europe. Edward 
Elgar, Cheltenham.  
NELSON, R. R., (Editor) (1993) National Innovation Systems. A Comparative Analysis, 
Oxford University Press. 
OECD (2002) Redefining Territories: The Functional Regions, Paris: OECD. 
OECD (2006) The Øresund Science Region: A cross-border partnership between Denmark and 
Sweden, Peer Review Report, OECD. 
30 
 
                                                                                                                                                                                     
PHARMACHEMICAL IRELAND (2011) Ireland: The Location of Choice for Scientific 
Investment. IBEC, Dublin.  
PISANO, G. (2006) Science Business: The Promise, the Reality, and the Future of Biotech. 
Harvard Business School Press, Boston, Massachusetts.  
PISANO, G. (2015) You need an innovation strategy (June Issue), Harvard Business Review.  
RAHM, D., KIRKLAND, J. and BOZEMAN, B. (2000) University-Industry R&D 
Collaboration in the United States, the United Kingdom, and Japan. Springer, London.  
REICHERTZ, J. (2007) Abduction: The logic of discovery of grounded theory. In: BRYANT, 
A. and CHARMAZ, K. (Eds.) The Sage Handbook of Grounded Theory, pp. 215-228, Los 
Angeles, CA: Sage.  
SENKER, J., ENZING, C., JOLY, P. and REISS, T. (2000) European exploitation of 
biotechnology – do government policies help. Nature Biotechnology 18, 605-609.  
SINGH, J. and AGRAWAL, A. (2011) Recruiting for ideas: how firms exploit the prior 
inventions of new hires. Manage. Sci. 57, 129–150. 
SPRU (2007) BioPolis - Inventory and analysis of national public policies that stimulate 
research in biotechnology, its exploitation and commercialisation by industry in Europe in the 
period 2002–2005. National Report of IRELAND.  
TER WAL, A.L.J. and BOSCHMA, R. (2011) Co-evolution of Firms, Industries and 
Networks in Space. Regional Studies 45, 919-933.  
31 
 
                                                                                                                                                                                     
TÖDTLING, F. and TRIPPL, M., 2005. One size fits all?: Towards a differentiated regional 
innovation policy approach. Research Policy 34, 1203-1219.  
VALE, M. and CARVALHO, L. (2013) Knowledge Networks and Processes of Anchoring in 
Portuguese Biotechnology, Regional Studies, Vol. 47, No. 7, 1018–1033. 
VINNOVA (2007) Effects of VINNVÄXT in Swedish Regions, Final Report.  
VINNOVA (2010) VINNVÄXT at the halfway mark: experiences and lessons learned. 
YIN, R. (1994) Case Study Research: Design and Methods (Applied Social Research 
Methods), 2nd ed. Sage Publication, USA.  
 
 
Fig. 1. Regional value-generation system 
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Table 1. Comparison of regional systems – the institutional dimension 
 Skåne Southern-Eastern 
National policies 
before mid-90’s                             
 Proactive science and technology 
policy for specific sectors 
 Systemic recognition on the 
importance of knowledge 
economy  
 Gradual recognition on the third 
role (developmental) of 
universities and research 
institutions  
 Orientation towards Foreign 
Direct Investments  
 Gradual recognition of the need 
to support indigenous industry 
and specific sectors 
 Formulation of strong 
enterprise base around 
academic centres business 
parks and across the region 
 
National policies 
since mid-90’s 
 
 National policies with adaptation 
to the regional needs  
 Supply-side oriented to support 
major institutions and champions 
such as LU and IDEON 
 System-oriented           
 Emphasis on the building of 
regionalised diffusion mechanisms 
and systemic relations          
 Regional governance retains a pro-
active role on the formulation of 
the regional innovation system and 
innovation policy implementation  
 Very strong presence on European 
support programmes and 
competitive Research Funds 
 Centrally designed in national 
level 
 Policy focused on few strategic 
sectors 
 Multi-level but fragmented with 
supporting mechanisms for 
indigenous and foreign-owned 
companies  
 Recognition of the need for 
systemic orientation 
 Regional governance retains a 
limited role on innovation 
policy design and 
implementation 
 Very active presence on 
European Structural Funds 
Source: ENTERPRISE IRELAND, 2011; FORFAS, 2011; VINNOVA, 2007, 2009a, 2009b, 2010; 
OECD, 2003. 
 
Table 2. Sector’s major features 
No of firms in operation by period No of firms in operation after 2006, by 
Period 
Total 
Universities’ 
spin-offs 
Origin Size 
Skåne S-E Skåne S-E  Skåne S-E  Skåne S-E 
Before 
1990 
8 16 4 0 Universities 
& institutes 
spin-offs 
37 28 Micro 52 24 
1991-
1995 
16  19 5 0 Small 8 25 
1996-
2000 
23  40 4  13 Large firms 
spin-outs 
3 7 Medium 8 12 
2001-
2005 
37  61 6 11 MNE’s 
subsidiaries 
2 17 Large - 6 
After 
2006 
68  67 18 4 Indigenous 
start-ups 
26 15   
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Source: FORFAS, 2009a, 2009b, 2011; VINNOVA, 2007, 2009a, 2009b, 2010; OECD, 2006; 
Organizations’ websites: European Patent Office/espacenet, IDA, Invest in Skane, Irish Software 
Association, Medicon Valley, Science Foundation Ireland, VINNOVA. 
 
Table 3. Segments, business models and source of co-funding 
No of firms in operation after 2006, by 
Segment Business model Source of co-funding 
 Skåne S-E  Skåne S-E  Skåne S-E 
Bio-pharma 36 25 Product 
oriented 
40 42 Venture 
Capital and/or 
supported by 
major bio-
pharma firms 
56 41 
Diagnostics  7 8 Platforms 
(Specialised 
Services)  
20 24 Publicly listed 
companies  
12 26 
Therapeutics 8 7 Therapies/ 
treatments 
8 1    
Bio-analytic 
services 
3 7      
Bio-materials  5 8     
Bio-food 4 6     
Other 5 6     
Source: FORFAS, 2009a, 2009b, 2011; VINNOVA, 2007, 2009a, 2009b, 2010; OECD, 2006; 
Organizations’ websites: European Patent Office/espacenet, IDA, Invest in Skane, Irish Software 
Association, Medicon Valley, Science Foundation Ireland, VINNOVA. 
 
Table 4. Regional systems’ business environment comparison 
 Skåne Southern Eastern 
Growth period  First companies established in 
the mid-80s till mid-90s 
 Acceleration starts at the 2000s  
 Most established by late 1990s, 
attracted by IDA initiatives. 
 Half of firms are MNEs or 
MNEs’ spin-outs. 
Structure of the 
sector 
 LU spin-offs are the drivers of 
activity 
 Employment is fragmented into 
a large number of micro & 
small firms 
 More than 20 MNE’s present in 
the region 
 MNE’s are the drivers of 
activity and employment 
Major segments  Bio-pharma 
 Therapeutics 
 Diagnostics 
 Bio-pharma 
 Diagnostics 
 Bio-materials  
 Bio-analytic services 
 Bio-food 
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Business models  DBF’S mostly oriented to 
intermediate biotechnology 
products such as active 
compounds, ingredients, kits or 
proteins 
 Specialised research providers 
 Firms with emphasis on new 
therapies or treatments based 
usually on patents.  
 Internationalisation depends on 
Medicon Valley/Copenhagen-
based firms 
 Over-reliance on knowledge 
exploration sphere which 
depends on public funding 
 MNE’s oriented to drug 
delivery 
 DBF’s dependence on MNE’s 
investments, activities and 
specialisations – benefited by 
MNEs’ international supply 
chains. 
 Over-reliance on public-backed 
VC mechanisms 
Major ownership 
schemes 
 Multi-partite schemes: Holding 
companies with VC 
participation 
 Publicly Listed Companies 
 Publicly backed VC companies 
Source of finance  National and international  
private VCs 
 Regional public & EU 
supported funding networks and 
organisations              
 Publicly supported VC 
mechanisms and schemes in 
national level  
 Lack of regional mechanisms  
 Lack of seed capital                                                                                                       
Strategic 
actors/couplings 
 Lund University 
 Medicon Valley 
 Pharmaceutical MNE’s 
 
 
Table 5. Summary of interviewees’ perceptions regarding the innovation policy and 
structures 
Key perceptions, Skåne Key perceptions, Southern-Eastern 
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 Radical shift towards innovation system 
approach since mid 1990s. Emphasis on: 
o public-private collaboration,  
o the ‘third’ role of universities (triple helix 
model) 
 Shift of responsibility for economic 
development: 
o ‘Functional Regions’  
o Regional Agreements 
o National policy actors, such as VINNOVA, 
direct regional policy & investment 
priorities 
o Compliance with the national policy 
objectives. 
 Explicit recognition for the strategic economic 
importance of life sciences and biotechnology 
by all the stakeholders – central factor to the 
regional agreements. 
 Many active regional networks and ‘triple 
helix’ type collaborations, especially in the 
Medicon Valley area: 
o Systemic role of LU in public-private 
partnerships and developing initiatives for 
knowledge exploration and exploitation,. 
o Major role of specialised regional 
knowledge transfer mechanisms, 
especially around LU. 
o Regional and national funding actors have 
evolved significantly, e.g. Universities’ 
holding companies and public-funded 
venture capitals.  
o Sector-oriented private funding 
mechanisms active in the region with 
national or international activity (e.g. 
Stockholm, Copenhagen) 
o Seed capital needs further maturity. 
 
 Gradual evolution to knowledge based 
economy and innovation systems mentality 
since late 1990s. 
o National policy actors are major 
funding mechanisms and drivers of 
change at the level of design and 
implementation; 
o National programmes, e.g. Technology 
Transfer Initiative, incubation and 
business supporting mechanisms 
ignited knowledge transformation 
activity – limited initial interest and 
scale of activities. 
o Need of a higher degree of 
coordination to create economies of 
scale and scope. 
 Regional development based on the EU co-
financed Operational Programme, with 
focus on developing infrastructure: 
o Regional agencies and assembles have 
partial role on design; 
o Fragmented and of limited scale. 
 Recognition of the biotechnology sector as 
a priority for industrial investment: 
o National mechanisms, e.g. Enterprise 
Ireland, backing public-private 
collaboration initiatives. 
o Universities and Technology Institutes 
still to fulfil their potential in 
knowledge exploration and 
knowledge exploitation. 
 Major role of MNEs: 
o Developed productive activity 
o Limited R&D capabilities or active and 
sustainable collaborations. 
 Seed and VC Schemes are mainly public-
backed initiatives 
 
APPENDIX 
Appendix A. The Institutional Formation in the two regions 
Table A.1. Organisations interviewed for this research 
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Skåne, Sweden Southern-Eastern, Ireland 
CIRCLE Lund University  
Öresund Food Platform 
LU Food Science AB 
Lund Bioinkubator 
IDEON Science Park/IDEON Innovation 
Öresund IT 
Öresund Entrepreneurship Platform 
Region Skåne/Invest in Skåne 
Connect Skåne 
LU Innovation 
IDA 
Forfas 
Science Foundation Ireland 
The National Institute for Bioprocessing 
Research and Training (NIBRT) 
University College Dublin technology transfer 
office 
Trinity Research & Innovation - Trinity College 
Enterprise Ireland 
Note: the interviews were conducted in August 2010 (Skåne) and September 2010 (Southern-
Eastern) 
 
 
Table A.2. Main National Actors 
Sweden Ireland 
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The Ministry of Enterprise, Energy and 
Communications, oversees VINNOVA;  
The Ministry for Research and Education;  
The Swedish Research Council FORMAS;  
Independent research foundations (e.g. Swedish 
Foundation for Strategic Research - SFF);  
The Swedish Agency for Economic and 
Regional Growth (Tillväxtverket – former 
NUTEK) 
The Department of Jobs, Enterprise and 
Innovation;  
Forfás; 
Industrial Development Agency (IDA);  
Enterprise Ireland (EI);  
Higher Education Authority (HEA) and  
Science Foundation Ireland (SFI) 
 
 
 
 
 
 
 
Table A.3. Programmes implemented in Skåne, on biotechnology 
Programme  Major beneficiary Contributors Outcome 
 
Year 
 
 
Swedish Competence 
Centres programme 
LU; Fifteen industrial 
partners (e.g. Active 
Biotech) 
 NUTEK 
one third private financial 
contribution 
BioSep Centre 
 
1995 
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Molecular and Cellular 
Plant Biology  
LU Swedish Foundation for 
Strategic Research (SSF) 
Basic research results  1996-2005 
Postgenomic Research 
and Technology 
Programme 
LU, Gothenburg 
University and Chalmers 
University of 
Technology in 
Gothenburg 
 
Wallenberg Foundation  
support by the SSF 
Swegene Centre for Integrative Biology 
(SCIBLU), LU 
1999 
Biomedical Centre 
(BMC) 
LU: over 100 research 
teams 
LU Basic and Applied research results 2001 
 
Biomolecular Dynamics  LU SSF Basic research results 2002-2004 
Lund Centre for Stem 
Cell Biology and Cell 
Therapy 
LU /BMC SSF One of the six Swedish strategic centres 
of excellence in life sciences. 
2003 
Food Innovation at 
Interfaces (FII)  
LU  
More than 140 
companies; 70 
researchers; 80 projects 
(FISKEN and 
RUTHERFORD, 2002) 
VINNOVA  LU launched the Lund Food Science 
Centre  
2003 
Linneaus grants 
 
Consortium of research 
groups, LU 
Swedish Research 
Council  
LU Diabetes Centre (LUDC) 2006 
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Clinical Research 
Centre 
Malmo Lund University; Region 
Skåne 
Basic research results  2006 
CREATE Health, a 
Strategic Centre for 
Translational Cancer 
research 
LU /BMC SFF, Knut and Alice 
Wallenberg Foundation 
and VINNOVA 
3 world-wide patents per year over the 
first five years; 6 spin-off firms, some 
already grown to more than 100 
employees (LAGNEVIC et al., 2003) 
2006 
VINN Excellence 
Centres 
LU industry 
collaboration (e.g. 
Aventure AB)  
VINNOVA (22 million 
euros for 10 years) 
Antidiabetic Food Centre (AFC); one of 
the fifteen excellence centres in Sweden 
2007 
 
 
 
 
 
 
 
Table A.4. Knowledge Transformation Organisations in Skåne, Life Sciences/Biotechnology 
Category/Name Location 
Science Parks 
IDEON Lund 
Medeon Malmo 
Krinova Science Park Krinova 
Incubators 
Ideon Innovation Lund 
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Lund Bioinkubator Lund 
Venture Lab Lund 
Lund Life Science Incubator (LLSI) Lund 
P.U.L.S. Helsinborg 
Alnarp Innovation Inkubator Alnarp 
Technology Transfer 
Lund University Innovation Systems AB (LUIS AB) Lund 
Forskarpatent i Syd AB Lund 
Innovation Office South-Innovationskontor Syd Blekinge, Kristianstad, Lund, Malmo, Alnarp 
Ideon Agro Food  Ideon Science Park 
Business support 
Teknoseed AB Lund 
Teknopol AB Lund 
Lund Development AB Lund 
LU Food Science AB  Lund 
LU BioScience AB Lund 
Högskolan Kristianstad Holding AB Kristianstad 
Innovator Skåne AB Lund 
Connect Skåne  Lund 
Technopol AB Lund 
 Innovationskontor Syd Lund 
SLU Holding AB Alnarp 
Funding mechanisms 
ALMI Lund 
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Technoseed AB Lund 
Innovation Bridge Lund 
LU University Bioscience AB (LU Bio) Lund 
LUBioAccelerator Lund 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A.5. Major programmes supported biotechnology in Southern-Eastern, 1998-2010  
Programme Major beneficiary Contributor Outcomes Year 
 
 
Principal Investigators  Academic/research 
centers 
SFI Academic/research centers 2000 
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Centres for Science, Engineering 
& Technology on Life Sciences 
UCC; DCU;  UCD SFI Alimentary Pharmabiotic Centre; Biomedical 
Diagnostics Institute; Systems Biology Ireland 
2000 
Strategic Research Clusters on 
Life Sciences 
UCD; UCD; UoL; 
TCD; UCD; DCU; 
DCU 
SFI Reproductive Biology Research Cluster; The 
Irish Drug Delivery Research Network; Solid 
State Pharmaceuticals Cluster; Immunology 
Research Centre; Advanced Biomimetics for 
Solar Energy Conversion; Irish Separation 
Science Cluster; Molecular Therapeutics for 
Cancer Ireland 
2000 
High Potential Start Ups Start-ups EI Start-ups  2004 
Programme for Research in Third-
Level Institutions 
RCSI HEA Institute of Biopharmaceutical Sciences 1999 
TCD Research Programme in Molecular Cell 
Biology 
2000 
RCSI Centre for Synthesis and Chemical Biology 2000 
NUIM Institute of Immunology 2000 
TCD Centre for Synthesis Chemical Biology 2000 
Institute of 
Technology, 
Carlow 
Biotechnology and Environmental Science 2001 
RCSI Biopharmaceutical Sciences Network 2001 
NUIM Institute of Bioengineering & Agroecology 2002 
TCD Trinity Centre for Bioengineering 2002 
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DCU National Institute for Cellular Biotechnology 2002 
UCC Analytical Biological Chemical Research 
Facility 
2002 
UCD Conway Institute of Biomolecular and 
Biomedical Research 
2003 
UCD/TCD Dublin Molecular Medicine Centre 2003 
RCSI Programme for Human Genomics 2004 
TCD Trinity Biomedical Sciences Institute 2011 
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Table A.6. Major Knowledge Diffusion Institutions in Southern-Eastern 
Category/Name Location 
Incubators with biotechnology activity in Institutes of Technology 
Learning & Innovation Centre (LINC)   Blanchardstown Institute of 
Technology 
DIT Incubation Centre Dublin Institute of Technology 
Enterprise Acceleration Centre  Limerick Institute of Technology 
Tom Creen Business Centre  Institute of Technology Tralee 
Arclabs Research and Innovation Centre  Waterford Institute of Technology. 
Bio-Incubators in Universities/Hospitals 
University College Cork Cork 
Dublin City University Dublin 
Trinity Technology & Enterprise Campus, TCD Dublin 
Nova UCD Dublin 
St. James Hospital Dublin 
 
Technology Transfer Mechanisms 
Technology Transfer Initiative National level/EI 
University College Dublin (UCD) Dublin 
Dublin City University (DCU) Dublin 
University College Cork (UCC) – BioTransfer Unit Cork 
NUI Maynooth Maynnoth 
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Trinity College Dublin Dublin 
Royal College of Surgeons Ireland (RCSI) Dublin 
Dublin Institute of Technology (DIT) Dublin 
University of Limerick (UL) Limerick 
Waterford Institute of Technology (WIT) Waterford 
           Funding from EI                         
Programme                                                                              Investments/millions 
Seed and Venture Capital Scheme, 1994- More than €350 
Irish BioScience Venture Capital Fund, 2001 €20 
European BioScience Fund I, 2002- €12.7 
Atlantic Bridge II Limited partnership Fund, 2010- €75 
Bank of Ireland Start-up and Emerging Sectors Fund, 
2010- 
€17 
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Appendix B. The Comparison of the two Regional Systems 
Table B.1. Comparison of regional systems – the institutional dimension 
  
Skåne 
 
Southern-Eastern 
 
National policies 
before mid-90’s                             
 Proactive science and 
technology policy for specific 
sectors 
 Systemic recognition on the 
importance of knowledge 
economy  
 Gradual recognition on the 
third role (developmental) of 
universities and research 
institutions  
 Orientation towards Foreign 
Direct Investments  
 Gradual recognition of the 
need to support indigenous 
industry and specific sectors 
 Formulation of strong 
enterprise base around 
academic centres business 
parks and across the region 
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National policies 
since mid-90’s 
 
 National policies with 
adaptation to the regional needs  
 Supply-side oriented to support 
major institutions and 
champions such as LU and 
IDEON 
 System-oriented           
 Emphasis on the building of 
regionalised diffusion 
mechanisms and systemic 
relations          
 Regional governance retains a 
pro-active role on the 
formulation of the regional 
innovation system and 
innovation policy 
implementation  
 Very strong presence on 
European support programmes 
and competitive Research 
Funds 
 Centrally designed in 
national level 
 Policy focused on few 
strategic sectors 
 Multi-level but fragmented 
with supporting mechanisms 
for indigenous and foreign-
owned companies  
 Recognition of the need for 
systemic orientation 
 Regional governance retains 
a limited role on innovation 
policy design and 
implementation 
 Very active presence on 
European Structural Funds 
Source: Appendix D, Table D.1 
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Table B2. Sector’s major features 
 
No of firms in operation by period No of firms in operation after 2006, by period 
Period Total Universities’ 
spin-offs 
Origin Size 
Skåne S-E Skåne S-E  Skåne S-E  Skåne S-E 
Before
1990 
8 16 4 0 Universities 
& institutes’ 
spin-offs 
37 28 Micro 52 24 
1991-
1995 
16 19 5 0 Small 8 25 
1996-
2000 
23 40 4 13 Large firms 
spin-outs 
3 7 Medium 8 12 
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2001-
2005 
37 61 6 11 MNE’s 
subsidiaries 
2 17 Large - 6 
After 
2006 
68  67 18 4 Indigenous 
start-ups 
26 15   
Source: Appendix D, Table D.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table B3. Segments, business models and source of co-funding 
No of firms in operation after 2006, by 
Segment Business model Source of co-funding 
 Skåne S-E  Skåne S-E  Skåne S-E 
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Bio-pharma 36 25 Product 
oriented 
40 42 Venture 
Capital and/or 
supported by 
major bio-
pharma firms 
56 41 
Diagnostics  7 8 Platforms 
(Specialised 
Services)  
20 24 Publicly listed 
companies  
12 26 
Therapeutics 8 7 Therapies/ 
treatments 
8 1    
Bio-analytic 
services 
3 7      
Bio-materials  5 8     
Bio-food 4 6     
Other 5 6     
Source: Appendix D, Table D.1 
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Table B.4. Regional systems’ business environment comparison 
 Skåne Southern Eastern 
Growth period  First companies established 
in the mid-80s till mid-90s 
 Acceleration starts at the 
2000s  
 Most established by late 
1990s, attracted by IDA 
initiatives. 
 Half of firms are MNEs or 
MNEs’ spin-outs. 
Structure of the 
sector 
 LU spin-offs are the drivers 
of activity 
 Employment is fragmented 
into a large number of micro 
& small firms 
 More than 20 MNEs present 
in the region 
 MNEs are the drivers of 
activity and employment 
Major segments  Bio-pharma 
 Therapeutics 
 Diagnostics 
 Bio-pharma 
 Diagnostics 
 Bio-materials  
 Bio-analytic services 
 Bio-food 
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Business models  DBF’S mostly oriented to 
intermediate biotechnology 
products such as active 
compounds, ingredients, kits 
or proteins 
 Specialised research 
providers 
 Firms with emphasis on new 
therapies or treatments based 
usually on patents.  
 Internationalisation depends 
on Medicon 
Valley/Copenhagen-based 
firms 
 Over-reliance on knowledge 
exploration sphere which 
depends on public funding 
 MNE’s oriented to drug 
delivery 
 DBF’s dependence on 
MNE’s investments, 
activities and specialisations 
– benefited by MNEs 
international supply chains. 
 Over-reliance on public-
backed VC mechanisms 
Major ownership 
schemes 
 Multi-partite schemes: 
Holding companies with VC 
participation 
 Publicly Listed Companies 
 Publicly backed VC 
companies 
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Source of finance  National and international  
private VCs 
 Regional public & EU 
supported funding networks 
and organisations              
 Publicly supported VC 
mechanisms and schemes in 
national level  
 Lack of regional mechanisms  
 Lack of seed capital                                                                                                       
Strategic 
actors/couplings 
 Lund University 
 Medicon Valley 
 Pharmaceutical MNEs 
 
 
 
Table B.5. Summary of interviewees’ perceptions regarding the innovation policy and 
structures 
Key perceptions, Skåne Key perceptions, Southern-Eastern 
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 Radical shift towards innovation system 
approach since mid 1990s. Emphasis on: 
o public-private collaboration,  
o the ‘third’ role of universities (triple 
helix model) 
 Shift of responsibility for economic 
development: 
o ‘Functional Regions’  
o Regional Agreements 
o National policy actors, such as 
VINNOVA, direct regional policy & 
investment priorities 
o Compliance with the national policy 
objectives. 
 Explicit recognition for the strategic 
economic importance of life sciences and 
biotechnology by all the stakeholders – 
central factor to the regional agreements. 
 Many active regional networks and ‘triple 
helix’ type collaborations, especially in the 
Medicon Valley area: 
o Systemic role of LU in public-private 
partnerships and developing initiatives 
for knowledge exploration and 
exploitation,. 
 Gradual evolution to knowledge based 
economy and innovation systems 
mentality since late 1990s. 
o National policy actors are major 
funding mechanisms and drivers of 
change at the level of design and 
implementation; 
o National programmes, e.g. 
Technology Transfer Initiative, 
incubation and business supporting 
mechanisms ignited knowledge 
transformation activity – limited 
initial interest and scale of 
activities. 
o Need of a higher degree of 
coordination to create economies 
of scale and scope. 
 Regional development based on the EU 
co-financed Operational Programme, 
with focus on developing 
infrastructure: 
o Regional agencies and assembles 
have partial role on design; 
o Fragmented and of limited scale. 
 Recognition of the biotechnology 
sector as a priority for industrial 
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Appendix C. Codification of the two distinctive Value Generation Systems 
 
Fig. C.1. The regional value-generation system of Skåne’s biotechnology sector 
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Fig. C.2. The regional value-generation system in Southern-Eastern’s biotechnology sector 
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